Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael M Miller

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Bioorganic & Medicinal Chemistry Letters|September 22, 2012
Identification of a potent and metabolically stable series of fluorinated diphenylpyridylethanamine-based cholesteryl ester transfer protein inhibitorsMichael M Miller, Yalei Liu, Ji Jiang, et al.
Science Translational Medicine|January 6, 2017
Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleedingPancras C Wong, Dietmar Seiffert, J Eileen Bird, et al.
Journal of Medicinal Chemistry|June 28, 2019
Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic EfficacyMichael M Miller, Jacques Banville, Todd J Friends, et al.
Journal of Medicinal Chemistry|November 3, 2015
Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (BMS-795311)Jennifer X Qiao, Tammy C Wang, Leonard P Adam, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Bioorganic & Medicinal Chemistry Letters|September 22, 2012
Identification of a potent and metabolically stable series of fluorinated diphenylpyridylethanamine-based cholesteryl ester transfer protein inhibitorsMichael M Miller, Yalei Liu, Ji Jiang, et al.
Science Translational Medicine|January 6, 2017
Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleedingPancras C Wong, Dietmar Seiffert, J Eileen Bird, et al.
Journal of Medicinal Chemistry|June 28, 2019
Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic EfficacyMichael M Miller, Jacques Banville, Todd J Friends, et al.
Journal of Medicinal Chemistry|November 3, 2015
Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (BMS-795311)Jennifer X Qiao, Tammy C Wang, Leonard P Adam, et al.
Pageof 4